Abstracts tagged "Lupus nephritis"

Abstract Number: 1478 • ACR Convergence 2023
Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review
Alain Sanchez-Rodriguez¹, Mariana Gonzalez-Treviño¹, Hannah Langenfeld², Cynthia Crowson³, Maria Valenzuela-Almada⁴, Alejandro Rabinstein⁵, Larry J. Prokop⁶, Isabel Valenzuela-Almada⁷ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Department of Pediatrics, Children’s National Medical Center, Washington, DC, ⁵Department of Neurology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁷Division of Internal Medicine, Hospital Medica Sur, Mexico City, Mexico
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…
Abstract Number: 1600 • ACR Convergence 2023
Transcriptomic Characterization of Class II Lupus Nephritis and Outcomes
Jasmine Shwetar¹, Katie Preisinger¹, Devyn Zaminski², Philip Carlucci¹, Kristina Deonaraine¹, Qian Xiao³, Joseph Mears⁴, Siddarth Gurajala³, Izmirly peter⁵, Judith James⁶, Joel Guthridge⁶, Andrea Fava⁷, Brad Rovin⁸, Wade DeJager⁶, Ming Wu⁹, Deepak Rao¹⁰, Chaim Putterman¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont², William Apruzzese¹⁰, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹⁰, Celine Berthier¹⁷, Maria Dall'Era¹⁸, Kerry Cho¹⁹, Diane L. Kamen²⁰, Kenneth Kalunian²¹, Jennifer Anolik²², Soumya Raychaudhuri¹⁰, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, David Wofsy¹⁸, Arnon Arazi²⁶, Kelly Ruggles⁹, Jill Buyon²⁵ and The Accelerating Medicines Partnership SLE/RA²⁷, ¹New York University School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU, New York, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Johns Hopkins University, Baltimore, MD, ⁸Ohio State University, Columbus, OH, ⁹NYU Langone, New York, NY, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of California San Francisco, San Francisco, CA, ¹⁹UCSF Health, San Francisco, CA, ²⁰Medical University of South Carolina, Charleston, SC, ²¹University of California San Diego, La Jolla, CA, ²²University of Rochester Medical Center, Rochester, NY, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Broad Institute of MIT and Harvard, Melrose, MA, ²⁷University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Lupus Nephritis (LN) significantly reduces the survival and life expectancy of patients with SLE. Given this, considerable effort has gone into characterizing the histologic…
Abstract Number: 2315 • ACR Convergence 2023
Assessing Lupus Disease Activity Following the Onset of End-Stage Kidney Disease Within a Single Tertiary Centre in South London
Samir Patel¹, Shounak Ghosh², Rajagopal Sankara Narayanan³, Letizia Valisena⁴, Deepak Nagra¹, Jonathan Dick⁴, Kate Bramham⁴, Patrick Gordon⁵ and Chris Wincup⁴, ¹King's College London, London, United Kingdom, ²CMRI Hospital, Kolkata, India, ³Narayana Medical College, Nellore, India, ⁴King's College Hospital, London, United Kingdom, ⁵NHS, London, United Kingdom
Background/Purpose: Lupus nephritis represents a severe manifestation of SLE and is associated with a risk of progression to end-stage kidney disease (ESKD) if untreated, leading…
Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 0915 • ACR Convergence 2023
IL-16+ Is Abundantly Expressed by Kidney-infiltrating Myeloid and Lymphoid Cells in Lupus Nephritis: A Spatially Resolved Multiplexed Approach
Alessandra Ida Celia¹, Xiaoping Yang², Hana Minsky², Silvia Malvica², Michelle Petri³, the Accelerating Medicines Partnership in RA/SLE⁴, Avi Rosenberg⁵ and Andrea Fava², ¹John Hopkins University of Medicine, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴Multiple, Multiple, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We previously discovered that IL-16 is the urinary protein most strongly correlated with histological activity in lupus nephritis (LN), followed by neutrophil degranulation products…
Abstract Number: 1480 • ACR Convergence 2023
Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region
Jamal Al-Saleh¹, Faisal Elbadawi¹, Rajaie Namas², Samar Al-Emadi³, Khalid A. Alnaqbi⁴, Humaid A. Al-Wahshi⁵, Amjad Alkadi⁶, Suad Hannawi⁷, Mohamed Hamouda⁸, Averyan Vasylyev⁸, Arwa Al-Shujairi⁸, Reem Al-Jayyousi⁹ and Munther Khamashta⁸, ¹Dubai Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Department of Rheumatology, Abu Dhabi, United Arab Emirates, ³Hamad Medical Corporation, Department of Rheumatology, Doha, Qatar, ⁴Tawam Hospital, Department of Rheumatology, Al Ain, United Arab Emirates, ⁵The Royal Hospital, Department of Rheumatology, Muscat, Oman, ⁶Ministry of Health, Kuwait, Kuwait, ⁷Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ⁸GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁹Mohamed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, United Arab Emirates, and Mediclinic Parkview, Dubai, United Arab Emirates
Background/Purpose: Data from limited studies of LN in the Gulf region suggest that LN manifests more severely in this region than in Caucasian populations, yet…
Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Joshua Skydel¹, Reshma Ramachandran², Sakinah Suttiratana², Joseph Ross², Joshua Wallach³ and Christopher Burns⁴, ¹Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Yale University, New Haven, CT, ³Emory University, Atlanta, GA, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
Abstract Number: 2326 • ACR Convergence 2023
Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
Emily Littlejohn¹, Salem Almaani², Vanessa Birardi³, Ernie Yap⁴ and Christopher Collins⁵, ¹Cleveland Clinic, Cleveland, OH, ²Ohio State University Medical Center, Columbus, OH, ³Aurinia Pharmaceuticals Inc, Edmonton, AB, Canada, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁵Formerly Aurinia Pharmaceuticals Inc., Copenhagen, Denmark
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis and is a mediator of progressive kidney damage. Early reductions in urine protein creatinine ratio…
Abstract Number: 0740 • ACR Convergence 2023
Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease
Shivani Garg¹, Brad Astor², S. Sam Lim³, Amish Raval², Weixiong Zhong², Sarah Panzer², Brad Rovin⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Emory University, Atlanta, GA, ⁴Ohio State University, Columbus, OH
Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…
Abstract Number: 0920 • ACR Convergence 2023
Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB
Xing Lyu¹, minghui li¹, ping zhang², Wei Wei³, victoria werth⁴ and Ming-Lin Liu⁵, ¹Tianjin Medical University, Tianjin, China, ²Beaumont Hospital Royal Oak, Royal Oak, MI, ³Tianjin Medical University General Hospital, Tianjin, China, ⁴University of Pennsylvania, Wynnewood, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening both skin lesions and systemic symptoms, i.e. lupus nephritis. We recently reported that UVB exposure…
Abstract Number: 1481 • ACR Convergence 2023
Racial Disparities in Lupus Nephritis: A Nationwide Analysis
Faria Sami¹, Shahzad Ahmed Sami², Augustine Manadan³ and Shilpa Arora¹, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²Trinity Health Oakland Hospital, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is a significant predictor of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Racial disparities are known to exist in SLE…
Abstract Number: 1652 • ACR Convergence 2023
Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders
Melicent Miller¹, Stephanie Slan¹, Rosalind Ramsey-Goldman², Rodlescia Sneed³, Candace Feldman⁴, Patrick Wildman¹, Tori Justin⁵, Lydia Oberholtzer⁵ and Joy Buie⁶, ¹Lupus Foundation of America, Washington, DC, ²Northwestern University, Chicago, IL, ³Wayne State University, Detroit, MI, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Sharp Insight, LLC, Montgomery County, MD, ⁶Lupus Foundation of America, York, SC
Background/Purpose: Black/African American people with lupus (PWL) experience greater disease prevalence and severity than White PWL. The need for more racial and ethnic diversity amongst…
Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
David Jayne¹, Eduardo Mysler², Zahir Amoura³, Patrick Gavin⁴, Erik Allman⁴, Cristina Di Poto⁴, Xiang Tian⁴, Sonja Hess⁴, Eszter Csomor⁵, Philip Brohawn⁴, Daniel Muthas⁵, Adam Platt⁶, Hussein Al-Mossawi⁶, Catharina Lindholm⁵ and Nicola Ferrari⁶, ¹University of Cambridge, Cambridge, United Kingdom, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
Abstract Number: 0781 • ACR Convergence 2023
Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Amit Saxena¹, Peter Izmirly², Jammie Law³, Cristina Sorrento³, H Michael Belmont⁴ and Jill Buyon⁵, ¹New York University Grossman School of Medicine, Rheumatology, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…
Abstract Number: 0921 • ACR Convergence 2023
SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis
Yevgeniya Gartshteyn¹, Leila Khalili², Laura Geraldino-Pardilla², Adam Mor³ and Anca Askanase⁴, ¹Columbia University Medical Center, New York, NJ, ²Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ³Columbia University, New York, NY, ⁴Columbia University Medical Center, New York, NY
Background/Purpose: Better understanding of the abnormal immune responses in lupus nephritis (LN) is fundamental to identifying new therapies. We previously reported that the adaptor protein…

« Previous Page
1
…
8
9
10
11
12
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].